BioPharma DiveOriginal article
FDA places partial hold on Biohaven’s epilepsy drug
RegulatoryopakalimNegative
AI Analysis
Summary
The FDA has placed a partial clinical hold on Biohaven's epilepsy drug opakalim, shortly after the company divested rights to the therapy. The halt affects a study that analysts consider potentially necessary for approval.
Outcome Details
FDA placed partial clinical hold
Importance:7/10
Sentiment:
-0.80
FDAclinical holdepilepsyregulatory setbackasset divestment
Related Companies
Read the original article
Published by BioPharma Dive on September 10, 2026 4:13 PM